01.04.2016 STRATEC Biomedical AG  DE000STRA555

DGAP-News: STRATEC completes acquisition of Diatron


 
DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition STRATEC completes acquisition of Diatron 01.04.2016 / 16:53 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STRATEC completes acquisition of Diatron Birkenfeld, April 1, 2016 STRATEC Biomedical AG, Birkenfeld, Deutschland (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Diatron MI PLC (Diatron). On March 23, 2016, STRATEC announced that it entered into an agreement with the global private equity firm The Riverside Company governing the full acquisition of Diatron, its US affiliate company and the superordinate holding structure. With the acquisition of Diatron, STRATEC is extending its range of products and its customer base in the hematology segment. Diatron's OEM portfolio chiefly comprises analyzer systems, system components, consumables and tests in the lower throughput segment for hematology applications. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Corporate Communications Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 [email protected] www.stratec.com --------------------------------------------------------------------------- 01.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: [email protected] Internet: www.stratec.com ISIN: DE000STRA555 WKN: STRA55 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX End of News DGAP News Service --------------------------------------------------------------------------- 450747 01.04.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 209,76 187,82 214,16 250,10 287,34 274,63 261,91
EBITDA1,2 47,33 35,53 35,60 56,27 66,43 58,07 40,08
EBITDA-Marge3 22,56 18,92 16,62 22,50 23,12 21,14
EBIT1,4 28,84 15,01 17,19 33,68 48,18 41,14 22,39
EBIT-Marge5 13,75 7,99 8,03 13,47 16,77 14,98 11,33
Jahresüberschuss1 25,64 8,97 14,41 25,18 39,96 29,22 13,07
Netto-Marge6 12,22 4,78 6,73 10,07 13,91 10,64 8,15
Cashflow1,7 29,98 11,95 21,26 31,85 63,47 10,28 19,43
Ergebnis je Aktie8 2,22 0,75 1,20 2,07 3,28 2,41 1,07
Dividende8 0,80 0,82 0,84 0,90 0,95 0,97 0,77
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: RSM Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
Stratec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
STRA55 42,400 Halten 515,49
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
24,94 30,78 0,56 22,00
KBV KCV KUV EV/EBITDA
2,27 26,54 1,97 15,92
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,97 0,55 1,30 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 09.08.2024 25.10.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,85% -8,47% -6,92% -33,85%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu STRATEC Biomedical AG  ISIN: DE000STRA555 können Sie bei EQS abrufen


Medtech , STRA55 , SBS , XETR:SBS